Related Experiment Video

Updated: Mar 26, 2026

Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
10:59

Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases

Published on: November 18, 2013

18.9K

Association between Apolipoprotein C-III Gene Polymorphisms and Coronary Heart Disease: A Meta-analysis

Jing-Zhan Zhang1, Xiang Xie1, Yi-Tong Ma1

  • 1Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China.

Aging and Disease
|January 28, 2016
PubMed

Insights

Genetic variations in apolipoprotein C-III (APOC3) gene, specifically SstI and T-455C polymorphisms, are linked to increased risk of coronary heart disease (CHD). However, the C-482T polymorphism shows no significant association with CHD susceptibility.

Area of Science:

  • Genetics
  • Cardiovascular Disease Epidemiology

Background:

  • Polymorphisms in the apolipoprotein C-III (APOC3) gene are implicated in coronary heart disease (CHD) risk.
  • Previous studies on APOC3 gene polymorphisms and CHD have yielded conflicting results.

Purpose of the Study:

  • To conduct a comprehensive meta-analysis investigating the association between three main APOC3 gene polymorphisms (SstI, T-455C, C-482T) and CHD.
  • To provide a more precise estimation of the relationship between these genetic variations and CHD susceptibility.

Main Methods:

  • Systematic literature search of multiple databases (PubMed, Web of Science, Wanfang, SinoMed, CNKI).
  • Inclusion of 31 published studies examining APOC3 polymorphisms and CHD.
  • Statistical analysis using odds ratios (ORs) with 95% confidence intervals (CIs) under various genetic models, employing Review Manager and Stata software.

Main Results:

  • The APOC3 SstI polymorphism was significantly associated with increased CHD susceptibility (OR=1.14, P=0.003 for allelic contrast).
  • The APOC3 T-455C polymorphism also showed a significant association with increased CHD risk (OR=1.19, P<0.0001 for allelic contrast).
  • No significant association was found between the APOC3 C-482T polymorphism and CHD susceptibility across all genetic models.

Conclusions:

  • The APOC3 SstI and T-455C polymorphisms are confirmed to significantly increase susceptibility to coronary heart disease.
  • The APOC3 C-482T polymorphism does not appear to be associated with CHD risk based on current evidence.

Keywords:
APOC3Coronary heart diseaseMeta-analysisPolymorphism

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.7K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
67
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
552
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.6K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
113